首页> 外文期刊>Biomaterials >Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines
【24h】

Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines

机译:聚(丙基丙烯酸) - 肽纳米片作为提高新稻草癌疫苗的免疫原性的平台

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Cancer vaccines targeting patient-specific tumor neoantigens have recently emerged as a promising component of the rapidly expanding immunotherapeutic armamentarium. However, neoantigenic peptides typically elicit weak CD8+T cell responses, and so there is a need for universally applicable vaccine delivery strategies to enhance the immunogenicity of these peptides. Ideally, such vaccines could also be rapidly fabricated using chemically synthesized peptide antigens customized to an individual patient. Here, we describe a strategy for simple and rapid packaging of peptide antigens into pH-responsive nanoparticles with endosomal escape activity. Electrostatically-stabilized polyplex nanoparticles (nanoplexes) can be assembled instantaneously by mixing decalysine-modified antigenic peptides and poly(propylacrylic acid) (pPAA), a polyanion with pH-dependent, membrane destabilizing activity. These nanoplexes increase and prolong antigen uptake and presentation on MHC-I (major histocompatibility complex class I) molecules expressed by dendritic cells, resulting in enhanced activation of CD8+T cells. Using an intranasal immunization route, nanoplex vaccines inhibit formation of lung metastases in a murine melanoma model. Additionally, nanoplex vaccines strongly synergize with the adjuvant α-galactosylceramide (α-GalCer) in stimulating robust CD8+T cell responses, significantly increasing survival time in mice with established melanoma tumors. Collectively, these findings demonstrate that peptide/pPAA nanoplexes offer a facile and versatile platform for enhancing CD8+T cell responses to peptide antigens, with potential to complement ongoing advancements in the development of neoantigen-targeted cancer vaccines.
机译:靶向患者特异性肿瘤NeoAntigens的癌症疫苗最近被出现为快速扩增的免疫治疗植物的有希望的组成部分。然而,新茴香肽通常引发弱CD8 + T细胞应答,因此需要普遍适用的疫苗输送策略来增强这些肽的免疫原性。理想地,这种疫苗也可以使用与个体患者定制的化学合成的肽抗原迅速制造。在这里,我们描述了一种肽抗原简单快速地包装成具有内体逃逸活性的pH响应纳米颗粒的策略。静电稳定的多分布纳米颗粒(纳米片)可以通过混合癸晶修饰的抗原肽和聚(丙烯酸)(PPAA),用pH依赖性,膜不稳定活性来瞬间组装。这些纳米物质增加和延长抗原摄取和呈现由树突细胞表达的MHC-1(主要组织相容性复合体I)分子,导致CD8 + T细胞的激活增强。利用鼻内免疫途径,纳米片疫苗抑制鼠黑色素瘤模型中肺转移的形成。另外,纳米片疫苗与佐剂α-半乳糖基胺(α-高层)刺激耐磨的CD8 + T细胞反应强烈协同,显着提高小鼠的生存时间,具有建立的黑色素瘤肿瘤。总的来说,这些研究结果表明,肽/ PPAA纳米片提供了一种容易和多功能平台,用于增强CD8 + T细胞对肽抗原的反应,潜力可以补充新南尼靶向癌症疫苗的持续发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号